Suit Over Novartis Drug’s Bone Death Risk Heads To Jury

Law360, New York (May 14, 2013, 7:56 PM EDT) -- After 11 days of testimony from some 20 witnesses, jurors began deliberating Tuesday in the New Jersey mass tort lawsuit of a woman suing Novartis Pharmaceuticals Corp. for allegedly minimizing the risks of bone death in the jaw from its bone-strengthening drug Zometa.

Attorneys for plaintiff Beverly Meng said during closing arguments in New Jersey state court that internal Novartis emails show the company was more concerned about profits than providing oncologists with responsible warnings about links between osteonecrosis of the jaw, or ONJ, and bisphosphonates like Zometa, which the U.S. Food and Drug Administration approved in 2002 to help prevent...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS